MHC class I-presented tumor antigen appraisable for T-cell responses against ovarian cancer


  • Jing Yao Wang Departmentof Gynecology, Second Hospital of Tianjin Medical University; Department of Gynaecology and Obstetrics, Tangshan Maternal and Children Health Hospital
  • Nan Zhang Department of Orthopedics, Tangshan Kailuan General Hospital, Tangshan 063 000
  • Xiaojie Yang Department of Gynecology and Obstetrics, Tangshan Maternal and Children Health Hospital, Tangshan 063 000
  • Danli Gao Department of Gynecology and Obstetrics, Tangshan Maternal and Children Health Hospital, Tangshan 063000
  • Lirong Yin Department of Gynecology, Second Hospital of Tianjin Medical University, Tianjin 300211
  • Shuying Ji Department of Gynecology and Obstetrics, Tangshan Maternal and Children Health Hospital, Tangshan 063 000



MHC Class I, Ovarian cancer, T-Cell response, Tumor antigen


The purpose of this study is to assess whether MHC class I-presented tumor antigen is appraisable for T-cell responses against ovarian cancer. In ovarian cancer cell, human leukocyte antigen A2 (HLA-A2) associated with peptides was used to promote the activation of naive T cells so as to activate antigen-specific T cells. 7 or 4 patients were observed grade 1 or 2 injection site reactions, respectively. 5, 2 or 1 patients were observed grade 1, 2 or 3 pain reactions, respectively. 4 or 1 patients were observed grade 1 or 2 induration reactions. Total number mean value of patients experiencing response to the particular peptide was 7.73, and total number mean value of peptides to which the patients responded was 7.45. MHC class I-presented tumor antigen is appraisable for T-cell responses against ovarian cancer in China.


Download data is not yet available.
711 Read


Cao YH, Fan JW, Li AX, Liu HF, Li LR, Zhang CL, Zeng L, Sun ZZ. Identification of MHC I class genes in two Platyrrhini species. Am J Primatol. 2015, 10.1002/ajp.22372.

Catamo E, Zupin L, Crovella S, Celsi F, Segat L. Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. Hum Immunol. 2014; 75: 1225-31.

Chen D, Gaborieau V, Zhao Y, Chabrier A, Wang H, Waterboer T, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Bencko V, Janout V, Foretova L, Mates IN, Szeszenia-Dabrowska N, Boffetta P, Pawlita M, Lathrop M, Gyllensten U, Brennan P, McKay JD. A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity. Hum Mol Genet. 2015, 10.1093/hmg/ddv015.

Chen K, Wei H, Ling S, Yi C. Expression and significance of transforming growth factor-beta1 in epithelial ovarian cancer and its extracellular matrix. Oncol Lett. 2014; 8: 2171-74.

Chen LC, Lan H, Sun L, Deng YL, Tang KY, Wan QH. Genomic organization of the crested ibis MHC provides new insight into ancestral avian MHC structure. Sci Rep. 2015; 5: 7963.

Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 3297-99.

Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol. 2013; 191: 1567-77.

Haimiti A, Hailiman Y, Gulina A, Du J, Hao Z, Rong XL, Zainuer A, Qin W, Lalai S. Reduced expression of members of the MHC-I antigen processing machinery in ethnic Uighur women with cervical cancer in the Xinjiang region of China. Curr Oncol. 2014; 21: e67-74.

Kang K, Nho CW, Kim ND, Song DG, Park YG, Kim M, Pan CH, Shin D, Oh SH, Oh HS. Daurinol, a catalytic inhibitor of topoisomerase II alpha, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase. Int J Oncol. 2014; 45: 558-66.

Lisik W, Tejpal N, Gong Y, Skelton TS, Ganachari M, Bremer EG, Kloc M, Ghobrial RM. Down regulation of genes involved in T cell polarity and motility during the induction of heart allograft tolerance by allochimeric MHC I. PLoS One. 2009; 4: e8020.

Liu J, Zhang H, Jia L, Sun H. Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions. Mol Med Rep. 2015; 11: 1708-14.

Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y, Zhu LC, Zhang SL, Iwamori M. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep. 2010; 23: 833-41.

Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, Groger J, Minnerup J, Wiendl H, Meuth SG, Duning T. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging. 2015; 36: 81-89.

Mao HL, Pang Y, Zhang X, Yang F, Zheng J, Wang Y, Liu P. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Oncol Rep. 2013; 29: 515-22.

Meng CF, Su B, Li W. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells. Mol Med Rep. 2011; 4: 1273-78.

Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, Koba S, Thibodeau R, Nagase K, Simonson WT, Seo A, Koelle DM, Madeleine M, Bhatia S, Nakajima H, Sano S, Hardwick JS, Disis ML, Cleary MA, Becker JC, Nghiem P. Down-regulation of MHC-I expression is preva-lent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014; 2: 1071-79.

Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol. 2003; 15: 751-63.

Reynolds CJ, Jones C, Blohmke CJ, Darton TC, Goudet A, Sergeant R, Maillere B, Pollard AJ, Altmann DM, Boyton RJ. The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles. Immunology 2014; 143: 438-46.

Sanchez-Munoz A, Jurado JM, Perez-Ruiz E, Alba E. Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. Clin Transl Oncol. 2009; 11: 329-31.

Weston C, Connor J. Evidence for the influence of the iron regulatory MHC class I molecule HFE on tumor progression in experimental models and clinical populations. Transl Oncogenomics. 2014; 6: 1-12.

Yang Z, Liu YI, Wei X, Zhou X, Gong C, Zhang T, Jin P, Xu S, Ma D, Gao Q. Co-targeting EGFR and autophagy impairs ovarian cancer cell survival during detachment from the ECM. Curr Cancer Drug Targets. 2015; 15: 215-26.

Additional Files



How to Cite

Wang, J. Y., N. Zhang, X. Yang, D. Gao, L. Yin, and S. Ji. “MHC Class I-Presented Tumor Antigen Appraisable for T-Cell Responses Against Ovarian Cancer”. Bangladesh Journal of Pharmacology, vol. 10, no. 3, July 2015, pp. 524-8, doi:10.3329/bjp.v10i3.23076.



Research Articles